Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Altered orbitofrontal sulcogyral patterns in gambling disorder: a multicenter study.

Li Y, Wang Z, Boileau I, Dreher JC, Gelskov S, Genauck A, Joutsa J, Kaasinen V, Perales JC, Romanczuk-Seiferth N, Ruiz de Lara CM, Siebner HR, van Holst RJ, van Timmeren T, Sescousse G.

Transl Psychiatry. 2019 Aug 5;9(1):186. doi: 10.1038/s41398-019-0520-8.

2.

Burden of non-motor symptoms in unclear parkinsonism and tremor: A study with [123I]FP-CIT SPECT.

Jaakkola E, Joutsa J, Mäkinen E, Noponen T, Pitkonen M, Levo R, Mertsalmi T, Scheperjans F, Kaasinen V.

J Neurol Sci. 2019 Sep 15;404:124-127. doi: 10.1016/j.jns.2019.07.025. Epub 2019 Jul 19.

PMID:
31374410
3.

Bupropion Causes Misdiagnosis in Brain Dopamine Transporter Imaging for Parkinsonism.

Honkanen EA, Kemppainen N, Noponen T, Seppänen M, Joutsa J, Kaasinen V.

Clin Neuropharmacol. 2019 Jul 29. doi: 10.1097/WNF.0000000000000359. [Epub ahead of print]

PMID:
31361666
4.

No link between striatal dopaminergic axons and dopamine transporter imaging in Parkinson's disease.

Honkanen EA, Saari L, Orte K, Gardberg M, Noponen T, Joutsa J, Kaasinen V.

Mov Disord. 2019 Jun 24. doi: 10.1002/mds.27777. [Epub ahead of print]

PMID:
31234224
5.

Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System.

van Eimeren T, Antonini A, Berg D, Bohnen N, Ceravolo R, Drzezga A, Höglinger GU, Higuchi M, Lehericy S, Lewis S, Monchi O, Nestor P, Ondrus M, Pavese N, Peralta MC, Piccini P, Pineda-Pardo JÁ, Rektorová I, Rodríguez-Oroz M, Rominger A, Seppi K, Stoessl AJ, Tessitore A, Thobois S, Kaasinen V, Wenning G, Siebner HR, Strafella AP, Rowe JB.

Alzheimers Dement (Amst). 2019 Apr 2;11:301-309. doi: 10.1016/j.dadm.2019.01.011. eCollection 2019 Dec.

6.

Presynaptic striatal dopaminergic function in atypical parkinsonisms: A meta-analysis of imaging studies.

Kaasinen V, Kankare T, Joutsa J, Vahlberg T.

J Nucl Med. 2019 Apr 12. pii: jnumed.119.227140. doi: 10.2967/jnumed.119.227140. [Epub ahead of print]

PMID:
30979821
7.

Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects.

Johansson J, Hirvonen J, Lovró Z, Ekblad L, Kaasinen V, Rajasilta O, Helin S, Tuisku J, Sirén S, Pennanen M, Agrawal A, Crystal R, Vainio PJ, Alho H, Scheinin M.

Neuropsychopharmacology. 2019 Aug;44(9):1667-1673. doi: 10.1038/s41386-019-0368-x. Epub 2019 Mar 13.

PMID:
30867551
8.

Individual parkinsonian motor signs and striatal dopamine transporter deficiency: a study with [I-123]FP-CIT SPECT.

Mäkinen E, Joutsa J, Jaakkola E, Noponen T, Johansson J, Pitkonen M, Levo R, Mertsalmi T, Scheperjans F, Kaasinen V.

J Neurol. 2019 Apr;266(4):826-834. doi: 10.1007/s00415-019-09202-6. Epub 2019 Jan 28.

9.

Deep brain stimulation for monogenic Parkinson's disease: a systematic review.

Kuusimäki T, Korpela J, Pekkonen E, Martikainen MH, Antonini A, Kaasinen V.

J Neurol. 2019 Jan 18. doi: 10.1007/s00415-019-09181-8. [Epub ahead of print] Review.

PMID:
30659355
10.

Dopamine and eye movement control in Parkinson's disease: deficits in corollary discharge signals?

Railo H, Olkoniemi H, Eeronheimo E, Pääkkönen O, Joutsa J, Kaasinen V.

PeerJ. 2018 Dec 7;6:e6038. doi: 10.7717/peerj.6038. eCollection 2018.

11.

Dopamine synthesis capacity correlates with µ-opioid receptor availability in the human basal ganglia: A triple-tracer PET study.

Majuri J, Joutsa J, Arponen E, Forsback S, Kaasinen V.

Neuroimage. 2018 Dec;183:1-6. doi: 10.1016/j.neuroimage.2018.07.069. Epub 2018 Aug 2.

PMID:
30077742
12.

Season of death and nigral neuronal density in a high-latitude region.

Heiskanen L, Kivinen K, Gardberg M, Wahlsten P, Kaasinen V.

Neuropathol Appl Neurobiol. 2019 Apr;45(3):314-317. doi: 10.1111/nan.12496. Epub 2018 May 21. No abstract available.

PMID:
29753303
13.

Binge eating disorder and morbid obesity are associated with lowered mu-opioid receptor availability in the brain.

Joutsa J, Karlsson HK, Majuri J, Nuutila P, Helin S, Kaasinen V, Nummenmaa L.

Psychiatry Res Neuroimaging. 2018 Jun 30;276:41-45. doi: 10.1016/j.pscychresns.2018.03.006. Epub 2018 Mar 9.

PMID:
29655552
14.

Striatal dopamine in Parkinson disease: A meta-analysis of imaging studies.

Kaasinen V, Vahlberg T.

Ann Neurol. 2017 Dec;82(6):873-882. doi: 10.1002/ana.25103. Epub 2017 Dec 5. Review.

PMID:
29165839
15.

Serotonin transporter density in binge eating disorder and pathological gambling: A PET study with [11C]MADAM.

Majuri J, Joutsa J, Johansson J, Voon V, Parkkola R, Alho H, Arponen E, Kaasinen V.

Eur Neuropsychopharmacol. 2017 Dec;27(12):1281-1288. doi: 10.1016/j.euroneuro.2017.09.007. Epub 2017 Oct 9.

PMID:
29032922
16.

Ventral striatal dopaminergic defect is associated with hallucinations in Parkinson's disease.

Jaakkola E, Joutsa J, Mäkinen E, Johansson J, Kaasinen V.

Eur J Neurol. 2017 Nov;24(11):1341-1347. doi: 10.1111/ene.13390. Epub 2017 Aug 22.

PMID:
28834102
17.

Survival in Parkinson's disease in relation to striatal dopamine transporter binding.

Mäkinen E, Joutsa J, Vahlberg T, Kaasinen V.

Parkinsonism Relat Disord. 2017 Sep;42:66-72. doi: 10.1016/j.parkreldis.2017.06.013. Epub 2017 Jun 23.

PMID:
28662820
18.

Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease.

Saari L, Kivinen K, Gardberg M, Joutsa J, Noponen T, Kaasinen V.

Neurology. 2017 Apr 11;88(15):1461-1467. doi: 10.1212/WNL.0000000000003810. Epub 2017 Mar 10.

PMID:
28283599
19.

Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers.

Strafella AP, Bohnen NI, Perlmutter JS, Eidelberg D, Pavese N, Van Eimeren T, Piccini P, Politis M, Thobois S, Ceravolo R, Higuchi M, Kaasinen V, Masellis M, Peralta MC, Obeso I, Pineda-Pardo JÁ, Cilia R, Ballanger B, Niethammer M, Stoessl JA; IPMDS-Neuroimaging Study Group.

Mov Disord. 2017 Feb;32(2):181-192. doi: 10.1002/mds.26907. Epub 2017 Feb 2. Review.

20.

Dopamine and Opioid Neurotransmission in Behavioral Addictions: A Comparative PET Study in Pathological Gambling and Binge Eating.

Majuri J, Joutsa J, Johansson J, Voon V, Alakurtti K, Parkkola R, Lahti T, Alho H, Hirvonen J, Arponen E, Forsback S, Kaasinen V.

Neuropsychopharmacology. 2017 Apr;42(5):1169-1177. doi: 10.1038/npp.2016.265. Epub 2016 Nov 24.

21.

Unchanged long-term rural-to-urban incidence ratio of Parkinson's disease.

Isotalo J, Vahlberg T, Kaasinen V.

Mov Disord. 2017 Mar;32(3):474-475. doi: 10.1002/mds.26862. Epub 2016 Nov 10. No abstract available.

PMID:
27862325
22.

SNCA mutation p.Ala53Glu is derived from a common founder in the Finnish population.

Pasanen P, Palin E, Pohjolan-Pirhonen R, Pöyhönen M, Rinne JO, Päivärinta M, Martikainen MH, Kaasinen V, Hietala M, Gardberg M, Saukkonen AM, Eerola-Rautio J, Kaakkola S, Lyytinen J, Tienari PJ, Paetau A, Suomalainen A, Myllykangas L.

Neurobiol Aging. 2017 Feb;50:168.e5-168.e8. doi: 10.1016/j.neurobiolaging.2016.10.014. Epub 2016 Oct 19.

PMID:
27838048
23.

Dynamic Changes in Cortical Effective Connectivity Underlie Transsaccadic Integration in Humans.

Railo H, Tuominen J, Kaasinen V, Pesonen H.

Cereb Cortex. 2017 Jul 1;27(7):3609-3617. doi: 10.1093/cercor/bhw182.

PMID:
27365299
24.

Visual versus automated analysis of [I-123]FP-CIT SPECT scans in parkinsonism.

Mäkinen E, Joutsa J, Johansson J, Mäki M, Seppänen M, Kaasinen V.

J Neural Transm (Vienna). 2016 Nov;123(11):1309-1318. Epub 2016 Jun 20.

PMID:
27324804
25.

No relevant midbrain atrophy in Parkinson's disease.

Mäkinen E, Joutsa J, Isotalo J, Kaasinen V.

Acta Neurol Scand. 2016 Nov;134(5):378-381. doi: 10.1111/ane.12551. Epub 2016 Jan 6.

PMID:
27265349
26.

Clinical and imaging findings in Parkinson disease associated with the A53E SNCA mutation.

Martikainen MH, Päivärinta M, Hietala M, Kaasinen V.

Neurol Genet. 2015 Oct 15;1(4):e27. doi: 10.1212/NXG.0000000000000027. eCollection 2015 Dec.

27.

[Update on Current Care Guideline: Parkinson's disease].

Pekkonen E, Atula S, Autere J, Eerola-Rautio J, Kaasinen V, Kauppinen M, Martikainen K, Ruottinen H, Viljamaa M.

Duodecim. 2016;132(1):91-3. Finnish.

PMID:
27044185
28.

Ipsilateral deficits of dopaminergic neurotransmission in Parkinson's disease.

Kaasinen V.

Ann Clin Transl Neurol. 2015 Dec 5;3(1):21-6. doi: 10.1002/acn3.268. eCollection 2016 Jan.

29.

Predictors of normal and abnormal outcome in clinical brain dopamine transporter imaging.

Jaakkola E, Joutsa J, Kaasinen V.

J Neural Transm (Vienna). 2016 Mar;123(3):205-9. doi: 10.1007/s00702-015-1495-0. Epub 2015 Dec 16.

PMID:
26676600
30.

Pharmacotherapy and generic health-related quality of life in Parkinson's disease.

Järvelä JT, Kaasinen V.

Acta Neurol Scand. 2016 Sep;134(3):205-9. doi: 10.1111/ane.12531. Epub 2015 Nov 10.

PMID:
26553754
31.

Hypermetabolism of Olivary Nuclei in a Patient with Progressive Ataxia and Palatal Tremor.

Korpela J, Joutsa J, Rinne JO, Bergman J, Kaasinen V.

Tremor Other Hyperkinet Mov (N Y). 2015 Aug 31;5:342. doi: 10.7916/D8PV6JMT. eCollection 2015.

32.

[Parkinson's disease associated with a mutation in the PARK2 gene].

Kaasinen V, Hietala M, Kuoppamäki M.

Duodecim. 2015;131(12):1187-90. Finnish.

PMID:
26245049
33.

[Phenotype and incidence of Creutzfeldt-Jakob disease in Finland in 1997-2013].

Isotalo J, Gardberg M, Verkkoniemi-Ahola A, Paetau A, Martikainen MH, Korpela J, Rummukainen J, Jääskeläinen SK, Parkkola R, Kaasinen V.

Duodecim. 2015;131(5):465-74. Finnish.

PMID:
26237909
34.

Is Occipital Cortex a Valid Reference Region in 123I-FP-CIT SPECT Imaging?

Joutsa J, Johansson J, Kaasinen V.

Clin Nucl Med. 2015 Jul;40(7):615-6. doi: 10.1097/RLU.0000000000000794. No abstract available.

PMID:
26018714
35.

Dorsal-to-Ventral Shift in Midbrain Dopaminergic Projections and Increased Thalamic/Raphe Serotonergic Function in Early Parkinson Disease.

Joutsa J, Johansson J, Seppänen M, Noponen T, Kaasinen V.

J Nucl Med. 2015 Jul;56(7):1036-41. doi: 10.2967/jnumed.115.153734. Epub 2015 May 7.

36.

Midbrain-to-pons ratio in autopsy-confirmed progressive supranuclear palsy: replication in an independent cohort.

Kaasinen V, Kangassalo N, Gardberg M, Isotalo J, Karhu J, Parkkola R, Sonninen P.

Neurol Sci. 2015 Jul;36(7):1251-3. doi: 10.1007/s10072-015-2184-3. Epub 2015 Mar 25.

PMID:
25805708
37.

Dopaminergic function and intertemporal choice.

Joutsa J, Voon V, Johansson J, Niemelä S, Bergman J, Kaasinen V.

Transl Psychiatry. 2015 Mar 3;5:e520. doi: 10.1038/tp.2015.12. No abstract available.

38.

Effects of aging and gender on striatal and extrastriatal [123I]FP-CIT binding in Parkinson's disease.

Kaasinen V, Joutsa J, Noponen T, Johansson J, Seppänen M.

Neurobiol Aging. 2015 Apr;36(4):1757-1763. doi: 10.1016/j.neurobiolaging.2015.01.016. Epub 2015 Jan 22.

PMID:
25697414
39.

Akinetic crisis in Parkinson's disease is associated with a severe loss of striatal dopamine transporter function: a report of two cases.

Kaasinen V, Joutsa J, Noponen T, Päivärinta M.

Case Rep Neurol. 2014 Nov 26;6(3):275-80. doi: 10.1159/000369448. eCollection 2014 Sep.

40.

Dopaminergic function and intertemporal choice.

Joutsa J, Voon V, Johansson J, Niemelä S, Bergman J, Kaasinen V.

Transl Psychiatry. 2015 Jan 6;5:e491. doi: 10.1038/tp.2014.133. Erratum in: Transl Psychiatry. 2015;5:e520.

41.

Intravenous ethanol increases dopamine release in the ventral striatum in humans: PET study using bolus-plus-infusion administration of [(11)C]raclopride.

Aalto S, Ingman K, Alakurtti K, Kaasinen V, Virkkala J, Någren K, Rinne JO, Scheinin H.

J Cereb Blood Flow Metab. 2015 Mar;35(3):424-31. doi: 10.1038/jcbfm.2014.209. Epub 2014 Dec 10.

42.

Increasing age-adjusted male-to-female incidence ratio of Parkinson's disease.

Kaasinen V, Vahlberg T, Suominen S.

Mov Disord. 2015 Feb;30(2):286-8. doi: 10.1002/mds.26098. Epub 2014 Dec 5. No abstract available.

PMID:
25477236
43.

Impulse control disorders are associated with multiple psychiatric symptoms in Parkinson's disease.

Jaakkola E, Kaasinen V, Siri C, Martikainen K, Cilia R, Niemelä S, Joutsa J.

J Parkinsons Dis. 2014;4(3):507-15. doi: 10.3233/JPD-140351.

PMID:
25112222
44.

DRD2-related TaqIA genotype is associated with dopamine release during a gambling task.

Joutsa J, Hirvonen MM, Arponen E, Hietala J, Kaasinen V.

J Addict Med. 2014 Jul-Aug;8(4):294-5. doi: 10.1097/ADM.0000000000000037. No abstract available.

PMID:
25089954
45.

Mortality in Parkinson's disease is not associated with the severity of early dopaminergic defect.

Järvelä JT, Rinne JO, Eskola O, Kaasinen V.

Parkinsonism Relat Disord. 2014 Aug;20(8):894-7. doi: 10.1016/j.parkreldis.2014.05.010. Epub 2014 Jun 2.

PMID:
24928032
46.

Differences in striatal dopamine transporter density between tremor dominant and non-tremor Parkinson's disease.

Kaasinen V, Kinos M, Joutsa J, Seppänen M, Noponen T.

Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1931-7. doi: 10.1007/s00259-014-2796-5. Epub 2014 May 28.

PMID:
24867256
47.

Diagnostic accuracy of parkinsonism syndromes by general neurologists.

Joutsa J, Gardberg M, Röyttä M, Kaasinen V.

Parkinsonism Relat Disord. 2014 Aug;20(8):840-4. doi: 10.1016/j.parkreldis.2014.04.019. Epub 2014 Apr 26.

PMID:
24816002
48.

Unlike in clinical blindsight patients, unconscious processing of chromatic information depends on early visual cortex in healthy humans.

Railo H, Andersson E, Kaasinen V, Laine T, Koivisto M.

Brain Stimul. 2014 May-Jun;7(3):415-20. doi: 10.1016/j.brs.2014.01.060. Epub 2014 Mar 4.

PMID:
24698972
49.

Brain dopamine transporter binding and glucose metabolism in progressive supranuclear palsy-like creutzfeldt-jakob disease.

Rissanen E, Kaasinen V, Sonninen P, Röyttä M, Päivärinta M.

Case Rep Neurol. 2014 Jan 31;6(1):28-33. doi: 10.1159/000358483. eCollection 2014 Jan.

50.

[Impulse control disorders in Parkinson's disease].

Joutsa J, Kaasinen V.

Duodecim. 2013;129(22):2351-8. Review. Finnish.

PMID:
24397147

Supplemental Content

Loading ...
Support Center